Phase I/II Study of S-1, Cisplatin and Docetaxel in Patients with Advanced Gastric Cancer
Phase 1
- Conditions
- untreated advanced or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000000484
- Lead Sponsor
- Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active other malignancy 2) Interstitial pneumonitis, pulmonary fibrosis 3) Massive pleural effusion or massive ascites 4) Active infection 5) Watery diarrhea 6) Other uncontrolled severe illness 7) Brain metastases 8) Pregnant or lactating women 9) Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I: Maximum Tolerated Dose, Recommended dose Phase II: Response rate
- Secondary Outcome Measures
Name Time Method Toxicity, Progression free survival, Overall survival